Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 476Carcinoma, Hepatocellular 131Rectal Neoplasms 114Colonic Neoplasms 110Neoplasm Metastasis 62Pancreatic Neoplasms 54Liver Neoplasms 44Stomach Neoplasms 37Neoplasms 37Esophageal Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Colorectal Cancer Metastatic 19Ovarian Neoplasms 15Gastrointestinal Neoplasms 14Breast Neoplasms 13Biliary Tract Neoplasms 13Adenocarcinoma 11Lung Neoplasms 10Carcinoma, Renal Cell 10Digestive System Neoplasms 9Cholangiocarcinoma 9Intestinal Neoplasms 8Melanoma 7Gallbladder Neoplasms 7Glioblastoma 6Endometrial Neoplasms 6Uterine Cervical Neoplasms 5Triple Negative Breast Neoplasms 5Sarcoma 5Prostatic Neoplasms 5

Interventions

Enoxaparin 2Endoscopic Mucosal Resection 2Tranexamic Acid 1Tinzaparin 1Standard of Care 1Radiotherapy 1Proton Pump Inhibitors 1Pancreaticoduodenectomy 1Palliative Care 1Neuromuscular Blockade 1Lansoprazole 1Esomeprazole 1Data Collection 1Dalteparin 1Bevacizumab 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemorrhage × Bevacizumab × Gastrointestinal × Clear all
NCT07527832 2026-06-03

An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.

Pfizer

Completed
1,000 enrolled
Gastrointestinal

Hemorrhage, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡